Close Menu

NEW YORK – An artificial intelligence-powered algorithm appears to be comparable to human pathologists for scoring PD-L1 expression on tumor and immune cells for predicting immunotherapy response, a new analysis has shown. 

The data, which researchers from Bristol-Myers Squibb and PathAI, a provider of AI-powered technology for use in pathology services, presented at a recent immunotherapy conference, are of interest to drugmakers looking for scalable technology solutions to accurately and reproducibly assess PD-L1. 

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.